Pentosan polysulfate

Pentosan polysulfate
Clinical data
Trade names	Elmiron, Zycosan
Other names	PPS, (1->4)-β-Xylan 2,3-bis(hydrogen sulfate) with a 4 O-methyl-α-D-glucuronate
AHFS/Drugs.com	Monograph
License data	US DailyMed: pentosan polysulfate;
Routes of; administration	By mouth, intramuscular
ATC code	C05BA04 (WHO) G04BX15 (WHO), QC05BA04 (WHO), QG04BX15 (WHO) QM01AX90 (WHO);
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Excretion	Feces, urine
Identifiers
CAS Number	37300-21-3 ; as sodium: 140207-93-8;
PubChem CID	37720;
DrugBank	DB00686;
ChemSpider	34595 ;
UNII	F59P8B75R4; as sodium: 914032762Y;
KEGG	as sodium: D05428;
ChEMBL	ChEMBL4073796; as sodium: ChEMBL1201516;
CompTox Dashboard (EPA)	DTXSID10190764 ;
Chemical and physical data
Formula	C10H18O21S4
Molar mass	602.47 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O;
	InChI InChI=1S/C10H18O21S4/c11-3-1-26-10(8(31-35(22,23)24)5(3)28-32(13,14)15)27-4-2-25-9(12)7(30-34(19,20)21)6(4)29-33(16,17)18/h3-12H,1-2H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6+,7-,8-,9-,10+/m1/s1; Key:FCCNSUIJIOOXEZ-SJYYZXOBSA-N;
	(verify)

Pentosan polysulfate, sold under the brand name Elmiron among others, is a medication used for interstitial cystitis.^[1] Evidence of benefit, however, is mixed as of 2024.^[2] It is recommended that the medication be stopped if there is no improvement within 6 months.^[3] It was approved for medical use in the United States in 1996.^[1]^[4]^[5]

^ ^a ^b ^c ^d "Elmiron- pentosan polysulfate sodium capsule, gelatin coated". DailyMed. 10 November 2022. Retrieved 21 December 2022.
^ Cacciatore L, Territo A, Minore A, Testa A, Mantica G, Esperto F (2024). "Bladder Pain Syndrome (BPS): A Comprehensive Review of Treatment Strategies and Management Approaches". Research and Reports in Urology. 16: 273–282. doi:10.2147/RRU.S387749. PMC 11523923. PMID 39479186.
^ "Elmiron". www.ema.europa.eu. European Medicines Agency (EMA). 14 August 2018. Retrieved 19 June 2025.
^ Lindeke-Myers A, Hanif AM, Jain N (2022). "Pentosan polysulfate maculopathy". Survey of Ophthalmology. 67 (1): 83–96. doi:10.1016/j.survophthal.2021.05.005. PMID 34000253. S2CID 234767956.
^ "Elmiron (pentosan polysulfate sodium)" (PDF). FDA approval letter. U.S. Food and Drug Administration. 25 September 1996. Archived from the original (PDF) on 21 October 2020.

[Elmiron_FDA_label-1] "Elmiron- pentosan polysulfate sodium capsule, gelatin coated". DailyMed. 10 November 2022. Retrieved 21 December 2022.

[Cac2024-2] Cacciatore L, Territo A, Minore A, Testa A, Mantica G, Esperto F (2024). "Bladder Pain Syndrome (BPS): A Comprehensive Review of Treatment Strategies and Management Approaches". Research and Reports in Urology. 16: 273–282. doi:10.2147/RRU.S387749. PMC 11523923. PMID 39479186.

[EMA2025-3] "Elmiron". www.ema.europa.eu. European Medicines Agency (EMA). 14 August 2018. Retrieved 19 June 2025.

[pmid34000253-4] Lindeke-Myers A, Hanif AM, Jain N (2022). "Pentosan polysulfate maculopathy". Survey of Ophthalmology. 67 (1): 83–96. doi:10.1016/j.survophthal.2021.05.005. PMID 34000253. S2CID 234767956.

[5] "Elmiron (pentosan polysulfate sodium)" (PDF). FDA approval letter. U.S. Food and Drug Administration. 25 September 1996. Archived from the original (PDF) on 21 October 2020.

[1]

[2]

[3]

[4]

[5]